The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Pathological growth of cardiomyocytes (hypertrophy) is a major determinant for the development of heart failure, one of the leading medical causes of mortality worldwide. Here we show that the microRNA (miRNA)-212/132 family regulates cardiac hypertrophy and autophagy in cardiomyocytes. Hypertrophic stimuli upregulate cardiomyocyte expression of miR-212 and miR-132, which are both necessary and sufficient to drive the hypertrophic growth of cardiomyocytes. MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice. Both miR-212 and miR-132 directly target the anti-hypertrophic and pro-autophagic FoxO3 transcription factor and overexpression of these miRNAs leads to hyperactivation of pro-hypertrophic calcineurin/NFAT signalling and an impaired autophagic response upon starvation. Pharmacological inhibition of miR-132 by antagomir injection rescues cardiac hypertrophy and heart failure in mice, offering a possible therapeutic approach for cardiac failure. Heart failure is often a consequence of pathological growth of cardiomyocytes or cardiac hypertrophy. Here Ucar and colleagues report that the microRNAs miR-132 and miR-212 promote cardiac hypertrophy and inhibit autophagy in cardiomyocytes by downregulating the transcription factor FoxO3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, fine-tuning of FOXO3 levels has been achieved via a miRNA-132 antagonistic approach,157 that is currently clinically tested (NCT04045405).”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [157]
In the citing paper
“| Cardiomyopathies | Cardiomyocyte‐specific overexpression of miR‐212/132 | Pathological cardiac hypertrophy, heart failure, and premature death, after impaired autophagic response upon starvation | Ucar et al (2012) |”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al (2012)
In the citing paper
“Along similar lines, the cardiomyocyte‐specific overexpression of miRNAs invalidating the transcriptional activity of FOXO3 (Ucar et al, 2012) or activating MTORC1 (Li et al, 2017) precipitates cardiac function, leading to heart failure.”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Self-citationHomeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Control of translation and mRNA degradation by miRNAs and siRNAs: Table 1.
Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., & Parker, R. (2006) · Genes & Development · doi:10.1101/gad.1399806 · Cited by 2,060
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., Newman, J., Bronson, R. T., Crowley, D., Stone, J. R., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.019 · Cited by 1,590
Cited by
Items 401–500 of 609
Zhang, D., Yin, L., Lin, Z., Yu, C., Li, J., Ren, P., Yang, C., Qiu, M., & Liu, Y. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31046 · Cited by 11
“…in various physiological and pathological processes, including cell phenotype, proliferation, differentiation, and autophagy, as well as inflammatory responses, cancer, and even epigenetic regulation (Chiou et al., 2013; Hara et al., 2013; Ucar et al., 2012; Williams et al., 2008; Wu et al., 2020).”
Narasimhan, G., Carrillo, E. D., Hernández, A., García, M. C., & Sánchez, J. A. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000619 · Cited by 11
Fatimy, R. E., Boulaassafre, S., Bouchmaa, N., Khayari, A. E., Vergely, C., Malka, G., & Rochette, L. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111566 · Cited by 12
microRNA-144: the ‘what’ and ‘how’ of remote ischemic conditioning?
Przyklenk, K. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0429-6 · Cited by 10
“Of particular relevance: (1) changes in cardiac expression of miR-1, the most abundant miRNA in heart, as well as multiple other miRNAs, have been described in response to myocardial ischemia–reperfusion, and (2) the potential targets of these miRs include genes encoding key pro- teins involved in apoptosis, autophagy…”
Alteration in microRNA-25 expression regulate cardiac function via renin secretion
Li, H., Xie, Y., Liu, Y., Qi, Y., Tang, C., Li, X., Zuo, K., Sun, D., Shen, Y., Pang, D., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.02.029 · Cited by 10
Knockdown of KCNQ1OT1 attenuates cardiac hypertrophy through modulation of the miR-2054/AKT3 axis
Chen, Y., Zhang, Z., Zhu, D., Zhao, W., & Li, F. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-203 · Cited by 10
“MicroRNAs (miRNAs) are a group of non-coding RNAs that do not have protein-coding functions (12).”
BackgroundZhang, Y., Bai, H., Zhang, W., Gao, J., Gao, C., Deng, T., Liu, X., Sun, X., Liu, Y., Wang, N., et al. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113828 · Cited by 9
Zhang, B., Wu, H., Zhang, J., Cong, C., & Zhang, L. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04909-7 · Cited by 9
“According to a study by Ucar et al., the overexpression of miR-212 leads to the downregulation of Foxo3, subsequently impairing basal autophagy at normal levels and inducing severe heart failure in mice [63].”
Role of Autophagy in Myocardial Remodeling After Myocardial Infarction
Tian, R.-Z., Zhuang, D., Vong, C. T., He, X., Ouyang, Q., Liang, J.-H., Guo, Y.-P., Wang, Y., Zhao, S., Yuan, H., et al. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001646 · Cited by 9
Song, Q., Wang, P., Wu, Y., Yao, Z., Wang, W., Tang, G., & Zhāng, P. (2025) · PeerJ · doi:10.7717/peerj.18978 · Cited by 11
“…effect via the Na/K-ATPase signaling pathway, where its downregulation leads to increased cardiac fibrosis ( Drummond et al., 2016 ). miR-212/132 promotes LVH and heart failure by repressing FoxO3 under pressure overload conditions, with increased levels observed in CKD ( Ucar et al., 2012 ).”
Xiao, F., Li, H., Wang, J., Wu, H., Cai, Y., Wang, J., Che, H., Li, G., Xia, Z., Xie, Y., et al. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02146-5 · Cited by 14
“In PO-HCM, numerous microRNAs exhibit altered expression patterns and participate in critical biological processes such as cardiomyocyte growth, apoptosis, and stress response [ 37, 38].”
InfluentialNew Frontiers of microRNA in Heart Failure: From Clinical Risk to Therapeutic Applications
Fumarulo, I., Prisco, A. D., Salerno, E., Ravenna, S. E., Vaccarella, M., Garramone, B., Burzotta, F., & Aspromonte, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186361 · Cited by 11
“Across preclinical studies, miR-132 emerges as a necessary and sufficient driver of pathological cardiomyocyte growth and adverse remodeling, making it a therapeutic target for heart failure [49].”
Yang, F., You, X., Xu, T., Liu, Y., Ren, Y., Liu, S., Wu, F., Xu, Z., Zou, L.-J., & Wang, G. (2018) · International Heart Journal · doi:10.1536/ihj.17-498 · Cited by 9
Loscalzo, G., Scheel, J., Ibáñez-Cabellos, J. S., García-López, E., Gupta, S. K., García‐Giménez, J. L., Mena, S., Alfredo Perales, M., & Morales‐Roselló, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010293 · Cited by 12
“However, as indicated, its pivotal role relates with the regulation of several signaling pathways in neuronal development (neuronal morphogenesis and synaptic plasticity) [70–72] and in the regulation of cardiac hypertrophy and autophagy in cardiomyocytes [76,77].”
BackgroundSelf-citationFoxO3 Regulates the Progress and Development of Aging and Aging-Related Diseases
Chang, Z., He, Z., & Xia, J. (2022) · Current Molecular Medicine · doi:10.2174/1566524023666221014140817 · Cited by 10
Cardiac Disease Status Dictates Functional mRNA Targeting Profiles of Individual MicroRNAs
Matkovich, S. J., Dorn, G. W., Grossenheider, T. C., & Hecker, P. A. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001237 · Cited by 9
MiR-132 Regulates Rem Expression in Cardiomyocytes During Long-Term β-Adrenoceptor Agonism
Carrillo, E. D., Sampieri-Cabrera, R., Hernández, A., García, M. C., & Sánchez, J. A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374059 · Cited by 10
Hayat, M. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812146-7.00001-9 · Cited by 10
Zeng, Z., Wu, W., Peng, Q., Sun, Y., & Jian-xin, L. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10053 · Cited by 11
NRF1-enhanced miR-4458 alleviates cardiac hypertrophy through releasing TTP-inhibited TFAM
Yang, M., Zhang, J., Jin, X., Li, C., Zhou, G., & Feng, J. (2020) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-019-00419-3 · Cited by 9
MicroRNAs as monitoring markers for right-sided heart failure and congestive hepatopathy
Ionescu, R. F., & Creţoiu, S. M. (2021) · Journal of Medicine and Life · doi:10.25122/jml-2021-0071 · Cited by 9
Liu, H., Li, T., Dong, C., & Lyu, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264645 · Cited by 12
“osteoarthritic cartilage [37], Alzheimer’s disease [38], and cardiac hypertrophy [39].”
BackgroundTakasu, T. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00289 · Cited by 9
Haider, K. H., Khan, M., & Sen, C. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-820719-2.00015-6 · Cited by 9
Epigenetic Regulation in Heart Failure: Part I RNA
Salvo, T. G. D. (2015) · Cardiology in Review · doi:10.1097/crd.0000000000000071 · Cited by 9
Wang, J., Zhang, J., Ding, X., Wang, Y., Li, Z. ⁄., Zhao, W., Jia, J., Zhou, J., & Ge, J. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3370 · Cited by 13
Werner, T., Kunze, A.-C., Stenzig, J., Eschenhagen, T., & Hirt, M. N. (2019) · Scientific Reports · doi:10.1038/s41598-019-46818-0 · Cited by 10
MicroRNA: unveiling novel mechanistic and theranostic pathways in diabetic cardiomyopathy
De, A., Sarkar, A., Banerjee, T., Bhowmik, R., Sar, S., Shaharyar, M. A., Karmakar, S., & Ghosh, N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613844 · Cited by 9
“For example, miRNA-221 was demonstrated to be signi fi cantly increased in the heart tissue of diabetic mice (Ucar et al., 2012). miRNA-212 was identi fi ed as a regulator of ventricular hypertrophy by its direct modulation of Foxo3 .”
Reactive Oxygen Species-Mediated Diabetic Heart Disease: Mechanisms and Therapies
Reily-Bell, M., Bahn, A., & Katare, R. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0098 · Cited by 10
“Knock-down of miRNA-132 would combat not only ROS-related CVD but also aid in encouraging nonpathological recovery after injury (56, 170). miR-195. miR-195 originates from intron 7, located on chromosome 17p13.”
Autophagy and pressure overload-induced cardiac hypertrophy
Zeng, Y., Weiqiong, R., Wen, A.-Z., Zhang, W., Fan, F., & Chen, O.-Y. (2022) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2021.2024810 · Cited by 9
Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies
Laksono, S., Hosea, G. T., & Nurusshofa, Z. (2022) · Journal of Brown Hospital Medicine · doi:10.56305/001c.37850 · Cited by 10
Exercise Training-Induced MicroRNA Alterations with Protective Effects in Cardiovascular Diseases
Gao, J., Song, J., Yan, Y., Gokulnath, P., Vulugundam, G., Li, G., Zhan, Q., Jiang, F., Lin, L., & Xiao, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2409251 · Cited by 8
“The antagomir-132-3p injection, by inhibiting its target miR132-3p, can improve FOXO3 protein levels and attenuate calcineurin/nuclear factor of activated T cells (NFAT) signal transduction induced by pressure overload, thereby abrogating cardiac hypertrophy and HF [104].”
BackgroundProgenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors
Stougiannou, T. M., Christodoulou, K. C., Koufakis, T., Mitropoulos, F. A., Mikroulis, D. A., Mazer, C. D., & Karangelis, D. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904145 · Cited by 11
“…receptor (hypothyroid cell state), where only β -MyHC expression increases instead, as a result of fetal programming [33,34]; overexpression of certain miRNAs including miR – 132, has also been observed, in turn leading to FoxO3 repression, and calcineurin/NFAT signalling pathway activation [35].”
BackgroundMicroRNA as a novel component of the tissue renin angiotensin system
Obama, T., & Eguchi, S. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.07.004 · Cited by 8
Micro-RNA Feedback Loops Modulating the Calcineurin/NFAT Signaling Pathway
Kannambath, S. (2016) · Non-Coding RNA · doi:10.3390/ncrna2020003 · Cited by 7
“Apart from the immune cells, a number of studies have explored miRNA regulation on the calcineurin/NFAT signaling pathway in cardiac hypertrophy [19–24].”
BackgroundAt the heart of programming: the role of micro-RNAs
Siddeek, B., Mauduit, C., Yzydorczyk, C., Benahmed, M., & Siméoni, U. (2018) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174418000387 · Cited by 11
ZBTB38, a novel regulator of autophagy initiation targeted by RB1CC1/FIP200 in spinal cord injury
Chen, J., Li, Y., Wang, H., Zhang, Z., Yu, D., Xing, C., Li, J., Li, H., Li, J., & Cai, Y. (2018) · Gene · doi:10.1016/j.gene.2018.07.073 · Cited by 8
“However, excessive autophagy induction may trigger autophagic cell death, a programmed cell death that differs from apoptosis (Korkmaz et al., 2012; Menghini et al., 2014; Mikhaylova et al., 2012; Ucar et al., 2012; Wang et al., 2013a).”
BackgroundExercise mediates myocardial infarction via non-coding RNAs
Han, C., Zhai, C., Li, A., Ma, Y., & Hallajzadeh, J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1432468 · Cited by 7
“The disruption of miRNA-mediated autophagy pathway regulation contributes to maladaptive cardiac hypertrophy (29). miRNAs can also target genes involved in intracellular calcium handling, such as SERCA2A, and alterations in calcium homeostasis and signaling due to miRNA dysregulation can impair…”
RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management
Mohammadi, A., Karimian, A., Shokri, K., Mohammadi, A., Karzar, N. H., Bahar, R., Radfar, A., Pakyari, M., & Tehrani, B. N. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10603-4 · Cited by 8
“CDR132L, an ASO inhibiting miR-132, has shown potential in reducing cardiac fibrosis and preventing HF progression in preclinical models [91, 92].”
Hayat, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801043-3.00001-7 · Cited by 8
MicroRNAs in the Stressed Heart: Sorting the Signal from the Noise
Matkovich, S. J. (2014) · Cells · doi:10.3390/cells3030778 · Cited by 7
“Anti-miRs against miR-34a [98] and the miR-212/132 family [99] offer protection against cardiac pressure-overload while anti-miR-34 reagents also protect against age-dependent cardiac cell death and injury resulting from myocardial infarction [100]; an anti-miR-24 is able to improve the outcome of pressure-overload by…”
BackgroundGene therapy targeting miR‑212‑3p exerts therapeutic effects on MAFLD similar to those of exercise
Sun, B., Zhang, Y., Zhang, M., Liu, R., & Yang, W. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5219 · Cited by 7
“FGF21 is a myokine which can improve the metabolic regulation of systemic organs when produced by skeletal muscle in response to exercise (15).”
BackgroundViereck, J., & Thum, T. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.09.006 · Cited by 7
Self-citationSun, C., Tong, L., Zhao, W., Wang, Y., Yuan, M., Lin, L., Liu, B., Zhai, Y., Zhong, Z., & Li, X. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3607 · Cited by 7
Park, D., Lee, H., Kang, J. H., Kim, S.-M., Gong, J., & Cho, K. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy019 · Cited by 7
“…the gene or protein expression levels of the network components using mRNA-sequencing or biochemical experimental data obtained from previous studies (Nakamura et al., 2000; Cuenca et al., 2006; Yang et al., 2006; Loan Le et al., 2012; Song et al., 2012; Ucar et al., 2012; Zhao et al., 2016).”
MethodBuzaș, R., Rogobete, A. F., Popovici, S. E., Mateescu, T., Hoinoiu, T., Șorop, V.-B., Bratu, T., Ticlea, M., Popoiu, C. M., & Săndesc, D. (2018) · Journal of Cardiovascular Emergencies · doi:10.2478/jce-2018-0008 · Cited by 8
Wang, X.-Q.-Y., Xu, Z.-T., Zhang, G., Hou, N., Qinxing, M., Wei, J., Jiang, X., Liu, Y., & Luo, J. (2019) · Europe PMC (PubMed Central) · Cited by 7
Synaptotagmin‐7 mediates cardiac hypertrophy by targeting autophagy
Sun, T., Han, Y., Li, J., Wang, S., Jing, Z., Yan, Z., Zhou, L., Zuo, L., Yang, J., & Cao, J. (2023) · FEBS Journal · doi:10.1111/febs.16961 · Cited by 7
Lei, Z., Fang, J., Deddens, J. C., Metz, C. H. G., van Eeuwijk, E. C. M., el Azzouzi, H., Doevendans, P. A., & Sluijter, J. P. G. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00590 · Cited by 8
Cui, J., Lu, K., Shi, Y. P., Chen, B., Tan, S.-H., Gong, Z., & Shen, H. (2015) · Gene · doi:10.1016/j.gene.2015.06.040 · Cited by 7
MicroRNAs as mediators of cardiovascular disease: Targets to be manipulated
Lee, S. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i2.34 · Cited by 7
Roles of microRNAs in cardiorenal syndrome
Ren, Y., Lin, H., Guo, J., Su, X., Wang, L., & Qiao, X. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05253-8 · Cited by 6
Capirossi, G., Brasini, S., Tremoli, E., Binatti, A., & Roncarati, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199725 · Cited by 7
“Artificial circRNA sponges (cicmiRs) designed to bind hypertrophic miRNAs such as miR-132 and miR-212 [273] have demonstrated superior stability and efficacy compared to conventional linear miRNA inhibitors (antagomiRs), both in vitro and in vivo.”
Kaur, S., Bhatti, G. K., Khullar, N., & Bhatti, J. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102920 · Cited by 7
Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment
Edwards, N. C., Pavlovic, D., Ferro, C. J., & Townend, J. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01234-y · Cited by 6
“The potential of miRNA inhibitors targeting fibrotic pathways is an exciting area for future research in both CKD-CM and HFpEF 209,210 .”
Specific microRNAs for Modulation of Autophagy in Spinal Cord Injury
Visintin, R., & Ray, S. K. (2022) · Brain Sciences · doi:10.3390/brainsci12020247 · Cited by 6
Zhao, C., Lin, C., Zhang, B., Wang, P., Zhang, B., Yan, L. E., Wang, C., & Qiu, L. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.109670 · Cited by 6
Beneficial effects of miR-132/212 deficiency in the zQ175 mouse model of Huntington’s disease
Nateghi, B., Keraudren, R., Boulay, G., Bazin, M., Goupil, C., Canet, G., Loiselle, A., St‐Amour, I., Planel, E., Soulet, D., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1421680 · Cited by 6
“Interestingly, miR-132/212 deletion also impacts heart size and cardiac function in mice (Ucar et al., 2012; Lei et al., 2020).”
BackgroundLi, H., Li, C., Zheng, T., Wang, Y., Wang, J., Fan, X., Zheng, X., Tian, G., Yuan, Z., & Chen, T. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10360-2 · Cited by 8
“MiR-212/132 directly targets the anti-hypertrophic and pro-autophagic FoxO3 transcription factor [10].”
BackgroundCircular RNAs: Biogenesis, Functions, and Role in Myocardial Hypertrophy
Baulina, N., Сергеевич, К. И., Сергеевна, Ч. О., & Favorova, O. O. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924140013 · Cited by 7
“For instance, the circmiR sponge was created to target miR-132 and miR-212 [83] and stimulate cardio-myocyte growth [84].”
Pepe, G., Appierdo, R., Ausiello, G., Helmer‐Citterich, M., & Gherardini, P. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084224 · Cited by 7
“Conversely, the genetic loss-of-function of miR-212/132, or the use of an antagomir to reduce miR-132, suppresses pressure-overload-induced calcineurin/NFAT signaling, thereby attenuating the development of cardiac hypertrophy [66].”
BackgroundMicroRNAs in the failing heart – Novel therapeutic targets?
Gidlöf, O., & Erlinge, D. (2014) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2014.983965 · Cited by 6
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Kent, O. A., Steenbergen, C., & Das, S. (2018) · Journal of Visualized Experiments · doi:10.3791/57845 · Cited by 7
Cardiovascular Research in Germany
Heusch, G., Eschenhagen, T., & Dimmeler, S. (2017) · Circulation Research · doi:10.1161/circresaha.117.311132 · Cited by 6
The Potential of RNA Therapeutics in Treating Cardiovascular Disease
Mainkar, G., Ghiringhelli, M., & Zangi, L. (2025) · Drugs · doi:10.1007/s40265-025-02173-1 · Cited by 7
“In a murine model of pressure overload-induced cardiac hypertrophy, treatment with antagomirs targeting miR-132 prevented the increase in cardiomyocyte diameters and heart-to-body-weight ratios by upregulating the expression of the pro-autophagic transcription factor FoxO3 [86].”
Pharmacologic and Lifestyle Interventions to Modulate the Epigenome in Heart Failure
Venanzio, L. D., Atzemian, N., Weber, B. Y., Gorica, E., Kleeberger, J., Mohammed, S. A., Costantino, S., Dzemali, O., Ruschitzka, F. T., & Paneni, F. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.08.001 · Cited by 5
Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction
Packer, M., Ho, J. E., Petrie, M. C., Schiattarella, G. G., Butler, J., Lam, C. S. P., Vaduganathan, M., Zannad, F. M., & Borlaug, B. A. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103046 · Cited by 10
Feng, P., Yang, F., Zang, D., Bai, D., Xu, L., Fu, Y., You, R., Liu, T., & Yang, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05143-5 · Cited by 5
“Overexpression of miR-212/132 through the AAV9 vector resulted in reduced cardiac atrophy[103], decreased DOX-induced apoptosis, and prevention of myofibrillar damage.”
Circulating microRNAs in predicting fibrosis in hypertrophic cardiomyopathy: A systematic review
Mylavarapu, M., Kodali, L. S. M., Vempati, R., Nagarajan, J. S., Vyas, A., & Desai, R. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i5.106123 · Cited by 5
“A direct correlation was identified between the extent of fibrosis and miR-4454 expression in HCM patients ( r = 0.4856, P = 0.0256, R 2 = 0.2358), indicating its potential as a biomarker for myocardial fibrosis in HCM[16].”
InfluentialmiR-212 Promotes Cardiomyocyte Hypertrophy through Regulating Transcription Factor 7 Like 2
Yuan, J., & Yuan, G. (2022) · Mediators of Inflammation · doi:10.1155/2022/5187218 · Cited by 5
“Studies have shown that miR-212 plays a role in promoting CH, but its mechanism has not been fully revealed [16, 17].”
BackgroundAutophagy in striated muscle diseases
Bailin, P. L., Zhang, L., Zhang, L., & Han, R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1000067 · Cited by 7
“The defective autophagic response and HF are caused when FoxO3 is inhibited by cardiomyocyte-specific overexpression of miR-212/132 (43) or mTORC1 is activated by miR-199a (44).”
BackgroundPizzol, M. S. D., Ibelli, A. M. G., Cantão, M. E., Campos, F. G., de Oliveira, H. C., Peixoto, J. D. O., Fernandes, L. T., Tavernari, F. D. C., Morés, M. A. Z., Bastos, A. P. A., et al. (2024) · BMC Genomics · doi:10.1186/s12864-024-09983-9 · Cited by 7
“Studies have shown that miR-132 regulates FoxO3 expression, acting as anti-hypertrophic and pro-autophagic [69].”
BackgroundCircRNA-based AntimiR therapy: A novel approach to hypertension treatment
Tarhriz, V., Hosseini, K., Abkhooie, L., & Lazartigues, E. D. (2025) · Non-coding RNA Research · doi:10.1016/j.ncrna.2025.05.001 · Cited by 7
“Importantly, antagomir-mediated miR-132 blockade reverses hypertrophy and heart failure in mice, highlighting a promising treatment strategy for cardiac dysfunction ([97].”
Sadat‐Ebrahimi, S., & Aslanabadi, N. (2020) · Galen Medical Journal · doi:10.31661/gmj.v9i0.1818 · Cited by 7
Exploiting the hypoxia sensitive non-coding genome for organ-specific physiologic reprogramming
Bischof, C., & Krishnan, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.024 · Cited by 5
Zhao, G., He, J., Wang, Z., Bao, L., Cong, R., An, W., Zhao, X., & Liu, G. (2019) · Neuroreport · doi:10.1097/wnr.0000000000001339 · Cited by 5
Hayat, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802936-7.00001-5 · Cited by 5
A New Pathway for Sympathetic Cardioprotection in Heart Failure
Simpson, P. C. (2015) · Circulation Research · doi:10.1161/circresaha.115.307246 · Cited by 5
Exosomes from Stem Cells as Therapeutic Agents for Cardiovascular Regeneration
Narmi, M. T., Darbandi, N. B., Gharavi, A. T., Babaeizad, A., & Sheykhhasan, M. (2025) · Wiley eBooks · doi:10.1002/9781394313785.ch5 · Cited by 6
Zivalj, D., Schleicher, L. M. S., Kršek, A., Diamee, H. J. F., Raljević, D., & Batičić, L. (2026) · Life · doi:10.3390/life16030400 · Cited by 7
CircRNA Larp4b/miR-298-5p/Mef2c Regulates Cardiac Hypertrophy Induced by Angiotensin II
Xie, Q., Xu, X., Xiong, D., Yao, M., & Zhou, Y. (2023) · International Journal of Sports Medicine · doi:10.1055/a-2172-8171 · Cited by 4
Upregulation of Serum miR-132 and miR-152 in Vietnamese Patients with Heart Failure
Vu, D. M., Huynh, A. P., Nguyễn, N. N. Q., Võ, N. V. T., Luong, B. A., Nguyen, T. C., & Vũ, H. A. (2024) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2024.31.4.7 · Cited by 5
“It has been reported to target several key factors in HF, such as the anti-hypertrophic transcriptional factor Forkhead Box O3 (FoxO3) (19), the sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase (SERC2a) in heart contractility (20) and the Ras GTPase-activating protein 1 (RASA1) of angiogenesis (21).”
BackgroundMechanistic insight into the role of cardiac-enriched microRNAs in diabetic heart injury
Kura, B., Kindernay, L., Singla, D. K., Duľová, U., & Barteková, M. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00736.2024 · Cited by 8
Visco, V., Forte, M., Giallauria, F., D’Ambrosio, L., Piccoli, M., Schiattarella, G. G., Mancusi, C., Salerno, N., Cesaro, A., Perrone, M. A., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133166 · Cited by 7
“At the molecular level, the inhibition of miR-132 was reported to improve FOXO3-induced anti-hypertrophic and pro-autophagic effects in cardiomyocytes [139].”
Epigenetic Mechanisms in Heart Diseases
Yildiz, M. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38696 · Cited by 5
Interactions between noncoding RNAs as epigenetic regulatory mechanisms in cardiovascular diseases
Moukette, B. M., Barupala, N. P., Aonuma, T., Sepúlveda, M., Kawaguchi, S., & Kim, I. (2021) · Methods in cell biology · doi:10.1016/bs.mcb.2021.06.002 · Cited by 4
Guo, Y., Wu, D., Li, X., Wang, J., Li, H., Li, Y., Luo, D., Yi, F., & Zhang, D. (2024) · The FASEB Journal · doi:10.1096/fj.202301500r · Cited by 4
González‐Candia, A., Figueroa, E. G., & Krause, B. J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116318 · Cited by 4
Tekirdağ, K. A., Öztürk, D. G., & Gözüaçık, D. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0031-x · Cited by 6
MicroRNA regulators of cholinergic signaling link neuromuscular, cardiac and metabolic systems
Pienica, C., & Soreq, H. (2017) · Periodicum Biologorum · doi:10.18054/pb.v118i4.4472 · Cited by 4
Pharmacokinetic Studies of Antisense Oligonucleotides Using MALDI-TOF Mass Spectrometry
Herkt, M., Foinquinos, A., Bátkai, S., Thum, T., & Pich, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00220 · Cited by 4
“Administration of miR-132 inhibitors (antimiRs) inhibited the development of cardiac hypertrophy mimicking the effects seen in miR212/132 KO mice (Ucar et al., 2012).”
BackgroundSelf-citationHayat, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802937-4.00001-6 · Cited by 4
Sciarretta, S., FALCO, E. D., Frati, G., & Sadoshima, J. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.01.52 · Cited by 5
“Pharmacological inhibition of miR-132 reduced cardiac hypertrophy and heart failure induced by pressure overload (14).”
BackgroundLuo, J., Lai, Z., Shen, C., Liu, P., & Shi, H. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669673 · Cited by 4
“Previous studies have shown that miRNAs from the same family tend to regulate common gene expression [10] [11] and members from the same miRNA family are related to similar diseases [12] [13].”
MicroRNA‐132 is overexpressed in fetuses with late‐onset fetal growth restriction
Morales‐Roselló, J., Loscalzo, G., García-López, E., García‐Giménez, J. L., & Alfredo Perales, M. (2022) · Health Science Reports · doi:10.1002/hsr2.558 · Cited by 4
MicroRNA-132 Inhibition Prevents Myocardial Hypertrophy and Heart Failure in Pigs
Condorelli, G., & Ferrante, G. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.039 · Cited by 4
Ye, Q., Ren, M., Fan, D., Mao, Y., & Zhu, Y. Z. (2024) · Antioxidants · doi:10.3390/antiox13080958 · Cited by 4
“The miR-132 family also directly targets the pro-autophagy FoxO3 transcription factor [63]. miR-762 is significantly upregulated in septic acute kidney injury [64].”
BackgroundFang, X., Song, R., Wei, J., Liao, Q., & Zeng, Z. (2022) · Mediators of Inflammation · doi:10.1155/2022/9652169 · Cited by 3
“For example, in cardiac hypertrophic remodeling, miR-132 has been previously verified as a master switch [16] and is markedly increased in the early hypertrophic phase of HF [17], and in genetic or pharmacological studies, inhibition of miR-132 has the effect of reversing or preventing the progression of HF [18].”
BackgroundDeep phenotyping of miRNAs in exercise-induced cardiac hypertrophy and fibrosis
Pala, M., Yılmaz, Ş. G., Altan, M., Sönmez, O. F., Dinçer, Ş., Mengi, M., Karabulut, A., Tecellioğlu, F. S., Akbaş, F., Yildiz, M., et al. (2023) · Journal of Biosciences · doi:10.1007/s12038-023-00360-4 · Cited by 4
“Upregulation of miR-132 results in the development of pathological cardiac remodeling in transgenic mice (Ucar et al. 2012).”
BackgroundHan, H., Shi, H., Jiang, L., Zhang, D., Wang, H., Li, J., & Chen, L. (2024) · Toxicology Letters · doi:10.1016/j.toxlet.2024.05.010 · Cited by 3
Metadata
- Authors
- Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., Remke, J., Caprio, M., Jentzsch, C., Engelhardt, S., Geisendorf, S., Glas, C., Hofmann, T. G., Nessling, M., Richter, K., Schiffer, M., Carrier, L., Napp, L. C., Bauersachs, J., Chowdhury, K., & Thum, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- IRCCS San Raffaele Roma (IT)
- Technical University of Munich (DE)
- Max Planck Institute for Biophysical Chemistry (DE)
- German Cancer Research Center (DE)
- Mount Desert Island Biological Laboratory (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Chowdhury, Kamal
- Thum, Thomas
- ORCID
- Venue
- Nature Communications
- Published
- 2012-09-25
- Volume
- 3
- Issue
- 1
- Pages
- 1078-1078
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3657998
- OpenAlex
- W2101080348
- Cited by
- 610
- References
- 46
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 47 · 2023: 32 · 2022: 60 · 2021: 53 · 2020: 52 · 2019: 41 · 2018: 43 · 2017: 51 · 2016: 47 · 2015: 67 · 2014: 44 · 2013: 26
- FWCI
- 28.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Baden-Württemberg Stiftung
- Deutsches Krebsforschungszentrum
- Deutsche Forschungsgemeinschaft (DFG-TH903/10-1, 01EO0802, SCHI587/3)
- Bundesministerium für Bildung und Forschung (01EO0802)
- Max-Planck-Gesellschaft
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- miR-212, miR-132, cardiac hypertrophy, cardiomyocyte autophagy, heart failure, FOXO3, pressure overload, antagomir, cardiomyocyte-specific overexpression, starvation-induced autophagy
- MeSH terms
- Antagomirs, Animals, Autophagy, Cells, Cultured, Cardiomegaly, Male, Mice, Transgenic, Oligonucleotides, Calcineurin, Reverse Transcriptase Polymerase Chain Reaction, Myocytes, Cardiac, MicroRNAs, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.